Investigative protocols
View our library of investigative protocols to assist in the management of patient care.
Jump to investigative protocols for:
Coagulation tests
| Abbreviation | IP Title | Date |
|---|---|---|
| IP402 | 2020-01 | |
| IP405 | 2020-01 | |
| IP404 | 2020-01 | |
| IP147 | 2020-01 | |
| IP148 | 2020-01 | |
| PLASMIC Score for prediction of thrombotic microangiopathy associated with severe ADAMTS13 deficiency | IP149 | 2020-01 |
General biochemistry
| Abbreviation | IP Title | Date |
|---|---|---|
| IP051 | 2020-01 | |
| IP052 | 2020-01 | |
| IP081 | 2020-01 | |
| IP082 | 2020-01 | |
| IP083 | 2020-01 | |
| IP111 | 2020-01 | |
| IP092 | 2020-01 | |
| IP061 | 2020-01 | |
| IP163 | 2020-01 | |
| IP101 | 2020-01 | |
| IP091 | 2020-01 | |
| IP406 | 2020-01 | |
| IP504 | 2020-09 | |
| IP112 | 2020-09 | |
| IP084 | 2020-01 | |
| IP093 | 2020-01 | |
| IP086 | 2020-01 | |
| IP085 | 2020-01 | |
| IP071 | 2020-01 | |
| IP033 | 2020-01 | |
| IP034 | 2020-01 | |
| IP031 | 2020-01 | |
| IP032 | 2020-01 | |
| IP611 | 2020-01 | |
| IP022 | 2020-01 | |
| IP021 | 2020-01 | |
| IP171 | 2020-01 | |
| PBS criteria for Evolocumab (PCSK9i): Familial homozygous hypercholestolaemia |
IP164 | 2020-09 |
| PBS criteria for lipid-lowering drugs: Patients other than very high risk | IP162 | 2018-08 |
| PBS criteria for lipid-lowering drugs: Very high risk patients | IP161 | 2018-08 |
Immunology
| Abbreviation | IP Title | Date |
|---|---|---|
| IP511 | 2020-01 | |
| IP510 | 2020-01 | |
| IP506 | 2020-01 | |
| IP505 | 2020-01 | |
| IP507 | 2020-01 | |
| IP513 | 2020-01 | |
| Dosing of Rh D immunoglobulin (Anti-D) following fetomaternal haemorrhage quantitation | IP514 | 2023-05 |
Liver function tests
| Abbreviation | IP Title | Date |
|---|---|---|
| IP134 | 2020-09 | |
| IP131 | 2020-09 | |
| IP133 | 2020-01 | |
| IP113 | 2020-01 | |
| IP114 | 2020-01 | |
|
Evaluation of a moderate elevation of aminotransferase levels (ALT and AST) |
IP130 | 2020-09 |
| IP123 | 2020-09 | |
| IP116 | 2020-01 | |
| IP121 | 2020-01 | |
| IP122 | 2020-10 | |
| IP125 | 2020-01 | |
| IP126 | 2020-01 | |
| IP124 | 2020-09 | |
| IP115 | 2020-09 |
Microbiology
| Abbreviation | IP Title | Date |
|---|---|---|
| IP621 | 2020-01 | |
| IP625 | 2020-01 | |
| IP604 | 2020-01 | |
| IP619 | 2020-01 | |
| IP615 | 2020-01 | |
| IP630 | 2020-01 | |
| IP618 | 2020-01 | |
|
Suggested management of active Helicobacter pylori infection |
IP607 | 2023-11 |
| IP620 | 2020-01 | |
| IP613 | 2018-08 | |
| IP622 | 2018-08 | |
| IP617 | 2020-01 | |
| Zika virus | IP633 | 2020-01 |
Serology
| Abbreviation | IP Title | Date |
|---|---|---|
| Diagnosis of SARS-CoV-2 infections | IP635 | 2020-01 |
| IP139 | 2018-08 | |
| The serological response to Coxiella burnetii (Q fever) | IP636 | 2022-02 |
| IP612 | 2018-08 | |
|
Serological events in acute hepatitis A infection relative to ALT peak |
IP128 | 2018-08 |
| IP138 | 2018-08 | |
| IP137 | 2018-08 | |
|
Serological profile for acute hepatitis B and progression to chronic hepatitis B |
IP129 | 2020-01 |
| IP136 | 2020-01 | |
| IP512 | 2018-08 | |
| IP626 | 2020-01 | |
| IP501 | 2020-01 | |
| IP609 | 2020-01 | |
| Serological profiles for acute and chronic Q fever | IP637 | 2022-02 |
| IP610 | 2018-08 | |
| IP608 | 2018-08 |